Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 3Kidney Failure, Chronic 3Multiple Myeloma 2Carcinoma, Renal Cell 2Virus Diseases 1Renal Insufficiency, Chronic 1Kidney Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Oncolytic Virotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Bevacizumab 2valrubicin 1thymoglobulin 1ledipasvir, sofosbuvir drug combination 1hepatitis C immune globulin, human 1halofantrine 1VP-102 1Therapies, Investigational 1Tenofovir 1Rituximab 1Radiotherapy, Intensity-Modulated 1Papillomavirus Vaccines 1Nimorazole 1Mitomycin 1Lamivudine 1Kidney Transplantation 1Ipilimumab 1Interferons 1Influenza Vaccines 1Immunoglobulin G 1Imiquimod 1Gemcitabine 1Gels 1Fluorescent Antibody Technique 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Virus Diseases × Kidney Transplantation × Clear all
NCT01136395 2019-10-08

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

University of Giessen

Phase 2 Completed
85 enrolled

Virus Diseases, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡